Gilberto Lopes

lopes 210




 Editor-in-Chief, JCO Global Oncology, American Society of Clinical Oncology
  • MD, MBA, FASCO @glopesMD
  • Professor of Clinical Medicine, Medical Director for International Programs, Associate Director for Global Oncology, Interim Chief, Division of Medical Oncology, Sylvester Comprehensive Cancer at the University of Miami
  • Member of the board of directors and co-Chair ATOM coalition,  Union International for Cancer Control

Gilberto Lopes is medical director for international programs and associate director for the Sylvester Comprehensive Cancer Center at the University of Miami, chief of the medical oncology division and professor of clinical medicine at the Miller School of Medicine. He currently serves in the board of directors for the Union International for Cancer Control and as Editor-in-Chief for the American Society of Clinical Oncology’s JCO Global Oncology. He completed medical school at the Federal University of Rio Grande do Sul in Brazil and residency in internal medicine, chief residency and hematology and medical oncology fellowship at the University of Miami and Jackson Memorial Hospital. He was assistant professor of oncology at the Johns Hopkins University and senior consultant and associate director for clinical research at the Johns Hopkins Singapore International Medical Center and served as Chief Medical and Scientific Officer for the Oncoclinicas group, the largest oncology provider in Latin America and one of the largest in the world.

Dr. Lopes has published more than 200 papers and book chapters in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet, Lancet Oncology and Health Affairs. In addition to delivering lectures around the world, he has been principal, co-Principal Investigator or steering committee member in more than 150 studies and clinical trials covering breast, gastrointestinal, genitourinary and thoracic cancers. His other main areas of research interest are disparities, health economics, value, policy and access to cancer drugs and care in low and middle-income countries.


Updated: June 2022